STRATA CRITICAL MEDICAL, INC. Selling and Marketing Expense
STRATA CRITICAL MEDICAL, INC. (SRTA) reported Selling and Marketing Expense of $482.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2025-11-10
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for the quarter ending 2025-09-30 was $482.00K, a 53.50% increase year-over-year.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for the quarter ending 2025-06-30 was $1.63M, a 31.80% decline year-over-year.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for the quarter ending 2025-03-31 was $1.44M, a 32.57% decline year-over-year.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for the quarter ending 2024-12-31 was $6.92M, a 186.99% increase year-over-year.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for fiscal 2024 was $7.95M, a 23.84% decline from fiscal 2023.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for fiscal 2023 was $10.44M, a 34.70% increase from fiscal 2022.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for fiscal 2022 was $7.75M.
- STRATA CRITICAL MEDICAL, INC. selling and marketing expense for fiscal 2021 was $2.79M, a 9.95% increase from fiscal 2020.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $482.00K 10-Q · filed 2025-11-10 | $2.12M derived: sum of 2 quarters · filed 2025-11-10 | $1.10M 10-Q · filed 2025-11-10 | $10.48M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2025-06-30 | $1.63M 10-Q · filed 2025-08-05 | $3.07M 10-Q · filed 2025-08-05 | $9.99M derived: sum of 3 quarters · filed 2025-08-05 | $10.31M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2025-03-31 | $1.44M 10-Q · filed 2025-05-12 | $8.36M derived: sum of 2 quarters · filed 2025-05-12 | $8.67M derived: sum of 3 quarters · filed 2025-11-10 | $11.07M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-12-31 | $6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $7.24M derived: sum of 2 quarters · filed 2025-11-10 | $9.63M derived: sum of 3 quarters · filed 2025-11-10 | $7.95M 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $314.00K 10-Q · filed 2025-11-10 | $2.16M 10-Q · filed 2024-11-12 | $2.71M derived: sum of 2 quarters · filed 2025-11-10 | $1.02M 10-Q · filed 2025-11-10 | $6.69M 10-Q · filed 2024-11-12 | $7.25M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $2.40M 10-Q · filed 2025-08-05 | $4.52M 10-Q · filed 2025-08-05 | $6.94M derived: sum of 3 quarters · filed 2025-08-05 | $9.62M derived: sum of 4 quarters · filed 2025-08-05 | |||
| 2024-03-31 | $2.13M 10-Q · filed 2025-05-12 | $4.54M derived: sum of 2 quarters · filed 2025-05-12 | $7.23M derived: sum of 3 quarters · filed 2025-05-12 | $9.96M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.10M derived: sum of 2 quarters · filed 2025-03-13 | $7.83M derived: sum of 3 quarters · filed 2025-03-13 | $10.44M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $2.69M 10-Q · filed 2024-11-12 | $5.41M derived: sum of 2 quarters · filed 2024-11-12 | $8.03M 10-Q · filed 2024-11-12 | $10.48M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $2.73M 10-Q · filed 2024-08-08 | $5.34M 10-Q · filed 2024-08-08 | $7.79M derived: sum of 3 quarters · filed 2024-08-08 | $9.65M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $2.61M 10-Q · filed 2024-05-07 | $5.07M derived: sum of 2 quarters · filed 2024-05-07 | $6.92M derived: sum of 3 quarters · filed 2024-05-07 | $8.56M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $4.31M derived: sum of 2 quarters · filed 2024-03-12 | $5.95M derived: sum of 3 quarters · filed 2024-03-12 | $7.75M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $1.86M 10-Q · filed 2023-11-08 | $3.49M derived: sum of 2 quarters · filed 2023-11-08 | $5.29M 10-Q · filed 2023-11-08 | $6.67M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $1.64M 10-Q · filed 2023-08-09 | $3.44M 10-Q · filed 2023-08-09 | $4.82M derived: sum of 3 quarters · filed 2023-08-09 | $6.05M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-11 | $3.18M derived: sum of 2 quarters · filed 2023-05-11 | $4.41M derived: sum of 3 quarters · filed 2023-05-11 | $5.03M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $1.38M 10-K · filed 2023-03-16 | $1.54M 10-QT · filed 2022-02-10 | $2.61M derived: sum of 2 quarters · filed 2023-03-16 | $3.23M derived: sum of 3 quarters · filed 2023-03-16 | $3.81M derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-09-30 | $1.23M 10-Q · filed 2022-11-10 | $1.85M derived: sum of 2 quarters · filed 2022-11-10 | $2.43M 10-Q · filed 2022-11-10 | $2.79M 10-K · filed 2023-03-16 | $3.46M 10-K · filed 2021-12-20 | ||
| 2021-06-30 | $615.00K 10-Q · filed 2022-08-09 | $1.20M 10-Q · filed 2022-08-09 | $1.64M derived: sum of 3 quarters · filed 2023-01-10 | ||||
| 2021-03-31 | $587.00K 10-Q · filed 2022-05-10 | $1.02M derived: sum of 2 quarters · filed 2023-01-10 | |||||
| 2020-12-31 | $435.00K 8-K · filed 2023-01-10 | ||||||
| 2020-09-30 | $2.53M 10-K · filed 2021-12-20 | ||||||
| 2019-09-30 | $5.01M 10-K · filed 2021-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |